Rosser, Anne Elizabeth ![]() |
Abstract
Clinical neural transplantation in Huntington's disease has moved forward as a series of small studies, which have provided some preliminary proof of principle that neural transplantation can provide benefit. However, to date, such benefits have not been robust, and there are a number of important issues that need to be addressed. These include defining the optimum donor tissue conditions and host characteristics in order to produce reliable benefit in transplant recipients, and whether, and for how long, immunosuppression is needed. Further clinical studies will be required to address these, and other issues, in order to better understand the processes leading to a properly functioning neural graft. Such studies will pave the way for future clinical trials of renewable donor sources, in particular, stem cell-derived neuronal progenitor grafts.
Item Type: | Book Section |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Biosciences MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Medicine Neuroscience and Mental Health Research Institute (NMHRI) |
Subjects: | R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry |
Uncontrolled Keywords: | clinical trials; Huntington's disease; human tissue; primary fetal tissue; transplantation |
Additional Information: | Functional Neural Transplantation III — Primary and Stem Cell Therapies for Brain Repair, Part I |
Publisher: | Elsevier |
ISSN: | 0079-6123 |
Last Modified: | 21 Oct 2022 10:55 |
URI: | https://orca.cardiff.ac.uk/id/eprint/41737 |
Citation Data
Cited 29 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |